AU2022387440A1 - Methods and compositions for treating conditions associated with central hypoventilation - Google Patents

Methods and compositions for treating conditions associated with central hypoventilation Download PDF

Info

Publication number
AU2022387440A1
AU2022387440A1 AU2022387440A AU2022387440A AU2022387440A1 AU 2022387440 A1 AU2022387440 A1 AU 2022387440A1 AU 2022387440 A AU2022387440 A AU 2022387440A AU 2022387440 A AU2022387440 A AU 2022387440A AU 2022387440 A1 AU2022387440 A1 AU 2022387440A1
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
nri
pharmaceutical composition
hypoventilation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022387440A
Other languages
English (en)
Inventor
Ronald FARKAS
Lawrence G. MILLER
Luigi TARANTO-MONTEMURRO
David P. WHITE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apnimed Inc
Original Assignee
Apnimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc filed Critical Apnimed Inc
Publication of AU2022387440A1 publication Critical patent/AU2022387440A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2022387440A 2021-11-11 2022-11-10 Methods and compositions for treating conditions associated with central hypoventilation Pending AU2022387440A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163278324P 2021-11-11 2021-11-11
US63/278,324 2021-11-11
US202263305305P 2022-02-01 2022-02-01
US63/305,305 2022-02-01
PCT/US2022/049483 WO2023086433A1 (en) 2021-11-11 2022-11-10 Methods and compositions for treating conditions associated with central hypoventilation

Publications (1)

Publication Number Publication Date
AU2022387440A1 true AU2022387440A1 (en) 2024-05-23

Family

ID=84627454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022387440A Pending AU2022387440A1 (en) 2021-11-11 2022-11-10 Methods and compositions for treating conditions associated with central hypoventilation

Country Status (9)

Country Link
US (1) US20250000823A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429649A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024541315A (cg-RX-API-DMAC7.html)
KR (1) KR20240108453A (cg-RX-API-DMAC7.html)
AU (1) AU2022387440A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237151A1 (cg-RX-API-DMAC7.html)
IL (1) IL312688A (cg-RX-API-DMAC7.html)
MX (1) MX2024005600A (cg-RX-API-DMAC7.html)
WO (1) WO2023086433A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025207125A1 (en) * 2024-03-26 2025-10-02 The Regents Of The University Of California Combination pharmacological interventions for obstructive sleep apnea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP3685858A1 (en) * 2019-01-24 2020-07-29 Assistance Publique-Hopitaux De Paris A noradrenergic system stimulator in the treatment of central hypoventilation syndromes
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea

Also Published As

Publication number Publication date
US20250000823A1 (en) 2025-01-02
EP4429649A1 (en) 2024-09-18
WO2023086433A1 (en) 2023-05-19
MX2024005600A (es) 2024-05-21
KR20240108453A (ko) 2024-07-09
JP2024541315A (ja) 2024-11-08
CA3237151A1 (en) 2023-05-19
IL312688A (en) 2024-07-01

Similar Documents

Publication Publication Date Title
US20250302808A1 (en) Dexmedetomidine treatment regimens
US20110070319A1 (en) Bifeprunox doses for treating schizophrenia
US20240189328A1 (en) Combination of norepinephrine reuptake inhibitor and a cannabinoid for use in treating sleep apnea
EP4429649A1 (en) Methods and compositions for treating conditions associated with central hypoventilation
TW200938194A (en) Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
US20230134935A1 (en) Medical use of daridorexant
US20240358709A1 (en) Methods and compositions for treating sleep apnea
CN118695856A (zh) 用于治疗与中枢性通气不足相关的疾患的方法和组合物
EP4313153A1 (en) Methods and compositions for treating sleep apnea
JP7556031B2 (ja) 認知症患者の行動心理学的症状の治療
IL230174A (en) Pharmaceutical composition for the treatment of premature ejaculation
TW202521100A (zh) 使用glp-1受體促效劑及第二活性劑之組合治療睡眠呼吸中止之方法及組合物
HK40112834A (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
EA045669B1 (ru) Способы лечения поведенческих и психологических симптомов у пациентов с деменцией
Ruscin Update on the role of anticholinergic drug therapy in the management of overactive bladder
HK1219669A1 (en) Dosage form containing oxycodone and naloxone
HK1219669B (en) Dosage form containing oxycodone and naloxone
HK1111604B (en) Dosage form containing oxycodone and naloxone
WO2014170353A1 (en) Nalmefene for treatment of patients with sleep disorder
HK1111604A1 (en) Dosage form containing oxycodone and naloxone
HK1204946B (en) Pharmaceutical compositions for combination therapy